CorEvitas
Overview
Operator of syndicated prospective observational registries, including nine autoimmune and inflammatory registries, spanning 400+ investigator sites and over 100,000 longitudinally followed patients in the US, Canada, and Japan. Provides regulatory-grade registry data and pharmacovigilance services to biopharma.
Notable
Formerly Corrona; acquired by Thermo Fisher Scientific for $912.5M in 2023 from Audax Private Equity.
Key services
- syndicated disease registries (RA, psoriasis, IBD, etc.)
- post-approval safety studies
- pregnancy registries
- registry-based RWE analytics
Subcategories
Verified Reviews
No verified reviews yet — are you a customer of CorEvitas? Share your experience in a short, confidential interview.
Share your experience